INDO AMERICAN JOURNAL OF PHARMACEUTICAL RESEARCH

FABRICATION OF EMBELIN INCORPORATED PHYTOSOMES COMPLEX FOR ASSESSING HEPATOPROTECTIVE POTENTIAL AGAINST ACETAMINOPHEN ELICIT HEPATOTOXICITY IN MALE WISTAR RATS.

Esha Yadav, Janey Alam*, Shiva, Sadaf Arfi, Mohammad Khalid, Pallavi Pal[2], Shahanuwaz Ahammad, Sadaf Hashmi

[1]*Axis Institute of Pharmacy, Kanpur-208001. Uttar Pradesh, India.*
[2]*Krishna Pharmacy College, Bijnor.*

ARTICLE INFO

Article history
Received 20/03/2023
Available online
10/04/2023

Keywords
Chitosan,
Soya Lecithin,
Embelin-Loaded Phytosome Complex,
Phytosome,
Entrapme,
Hepatoprotective Activity,
Paracetamol.

ABSTRACT

The purpose of this research was to see whether Wistar male rats might be protected against paracetamol-induced liver damage by ingesting Embelin-loaded phytosomes complex (EMBP) (PCM). Multiple pharmacological impacts of embelin have been identified, and this study aimed to reduce the required dose while increasing its bioavailability. The hepatotoxicity of paracetamol in Wistar male rats was reduced by belinostatin-loaded phytosomes complex (EMBP) (PCM). Animals group I were treated with 1% CMC for 8 days. PCM was given orally as a single dosage on the eighth day, after a seven-day treatment regimen of "1% CMC," 1 ml/kg per day of EMBP, 50 mg/kg per day of EMBP, 100 mg/kg per day of EMBP, and 100 mg/kg per day of silymarin. Following 24 hours, the animals were sacrificed and their blood was collected via the retro-orbital plexus while under light anaesthesia. In order to determine the hepatoprotective potential, many biochemical markers were analysed. Rats in group IV had significantly lower levels of ALP, AST, ALT, LDH, saturated fat, Total bilirubin, hepatic mass, and comparative hepatic mass contrasted to rats in group II, and higher levels of final body weight, total protein, and alanine aminotransferase (ALB) contrasted to rats in group II. Both silymarin and EMBP, at 100 mg/kg/day, have hepatoprotective potentials similar to those of the gold standard medication, silybin. The study's findings were supported by the histology analysis. Burmese Embelia ribes contained the active component embelin. We employed an innovative method of drug delivery called a phytosome. Six Embelin-loaded phytosome complicated compositions (EMBP1, EMBP2, EMBP3, EMBP4, EMBP5, and EMBP6) were made by combining soy lecithin and chitosan in different proportions and then utilising the anti-solvent precipitate technique as well as the Rotary evaporation technique. Characterization of the phytosome included (SEM) scanning electron microscopy, in vitro release studies, documented drug release kinetic investigations, particle size estimate, percentage output, as well as entrapment efficiency. Among the six formulas, EMBP5 was the most optimised. EMBP5 has the smallest diameter of 345.45±1.231. The immobilization of embelin inside the phytosome complex distinguish from 64.99±1.546 to 81.78±1.151%. The highest entrapment efficiency, 81.78±1.151%, is achieved using the formation of embelin-loaded phytosome complex (EMBP5). The optimal formulation of embelin-loaded phytosomes (EMBP5) was found to contain phytosomes that were less spherical, had a rough and smooth surface, as well as were somewhat aggregated. The phytosomes' in vitro dissolution research revealed a pattern of release. It was determined that fickian diffusion and first order kinetics were involved in the release of embelin from the complex of phytosomes containing embelin (concentration dependant).According to this study, EMBP has hepatoprotective properties equivalent to those of standard silymarin because it showed similar protective potential against acetaminophen-induced hepatotoxicity in male wistar rats.

Corresponding author
Janey Alam
Assistant Professor,
Axis Institute of Pharmacy, Kanpur,
Rooma (NH-2 Kanpur-Allahabad Highway),
Kanpur-208001. Uttar Pradesh India.
+91-9411072928.
janeyalam@axiscolleges.in

*Please cite this article in press as **Janey Alam** et al. Fabrication of Embelin incorporated Phytosomes complex for assessing hepatoprotective potential against acetaminophen elicit hepatotoxicity in Male Wistar rats. Indo American Journal of Pharmaceutical Research.2023:13(04).*

INTRODUCTION

Unlike the standard methods of medication distribution, innovative drug delivery systems do not have the drawbacks that older methods have. When administered via the standard, antiquated method for administering medication, the herbal remedy loses some of its efficacy[1]. Some herbs and herbal components may be more effective and have fewer side effects if modern medication delivery technology is used into herbal medicine. For this reason, a new medication delivery system has been used in herbal remedies[2].

Many plants, especially thathaving poly-phenolic nucleus throughout their compositions like terpenoids as well as flavonoids, have limited oral bioavailability, which poses a worry for scholars. as well as tannins[3,4]

Several strategies have been developed to improve medication absorption, including the development of, liposomes, nano-emulsionsand nanomaterials, in addition to the metamorphose of chemical compounds and enunciation of prodrugs. To increasebioavailability of active constituents,[5]phytosomes (also known as phyto-phospholipid complexes)emerged as a viable method.

Bioavailability may be improved by the Italian pharmaceutical as well as nutraceutical business Indena's novel approach of complexing plant extracts comprising water-soluble elements with phospholipids. They registered the trademark "PHYTOSOME®" for the technique. A plant is called a "phyto," and "some" refers to anything with the characteristics of a cell[6].

Phospholipids, such as phosphatidylcholine and polymer, react with standardized plant extracts, phytoconstituents, poly-phenolic or flavonoids of herbal ingredients like gingko, green tea, ginseng grape seed, hawthorn, milk thistle and aprotic diluent to produce phytosomes loaded with drug delivery systems[7]. Embelin is a compound found in the Myrsinaceae family of plants, and is especially abundant in the species Embelia and Ardisia sp (benzoquinone; Fig 1)[8]. Ebelin was a key component of Embelia ribes Burm. f., analgesic, antioxidant, antifertility anti-inflammatory, antidiabetic, anticonvulsant, anxiolytic,antibacterial activity and hepatoprotective are just some of the pharmacological effects seen with embelin[9].

When plant medicines or extracts are complexed with phospholipids or excipients, the bioavailability as well as beneficial vitality of certain weakly absorbed plant components are greatly increased. It was from this vantage point that the study was conducted. Embelin is poorly absorbed orally, is soluble in organic substances but not water, and is destroyed in the stomach. The studies looked at the feasibility of administering Embelin using a novel drug delivery method known as a phytosome[10,11] in order to boost its bioavailability, reduce the dose, and prevent its disintegration in the gastrointestinal tract.

The main goal of this scientific study project was to concentrate on using phospholipid and polymer to produce and characterise Embelin phytosomes. In order to achieve the goal, the entire research work was divided into the following phases.

To get pure Embelin, as well as phospholipids and polymers for formulations.The melting point, UV spectrum analysis, and FTIR (Fourier transform Infrared Spectroscopy and DSC (Differential Scanning Calorimetry)) spectrum analysis was used to identify and describe the Embelin.

To determine quantity of medicine (using FTIR) Spectroscopy & DSC) and conduct a drug-excipient compatibility study.Embelin phytosomes were created utilising phospholipid and polymer.Phytosomes created by Embelin were assessed and characterized.

They include measurements like percentage yield, particle identification, scanning electron microscopy (SEM), and others.

To test the entrapment effectiveness of phytosomes in vitro.To carry out an in-vitro drug release experiment. To investigate drug release kinetics using a variety of release kinetic models.

Resource and methods for EMBP

Procurement and identification of Embelin

Akums Drugs & Pharmaceuticals Ltd. in Haridwar, India generously sent a free sample of their drug Embelin for our use (India). The pure Embelin we saw was brown to slightly yellowish powder.

Physical compatibility (Drug-excipient research)

Phytosomes are formed from phospholipids as well as a polymer, hence the purity of Embelin was looked at. The mixture consists of 100% pure embelin, soy lecithin, as well as chitosan in a 1:1:1 ratio. Embelin's compatibility with phospholipids and polymers was analysed using Fourier Transform Infrared Spectroscopy. Embelin's IR spectra, as well as those of phospholipids and polymers, were recorded employing FTIR spectroscopy (Shimadzu-8404 S, Japan).

Embelin and its physical mixing with soy lecithin and chitosan[12] were the subject of a DSC (Differential Scanning Calorimetry, Shimadzu DSC-55, Japan)[13] investigation for some further compatibility study.

Formulation of Embelin loaded phytosome complex

The "Anti-solvent precipitate technique" as well as the "Rotary condensation method" were used to develop Embelin complicated compositions packed with phytosomes. Sixth-generation compositions of phytosomes loaded with embelin were developed (Table 1).

Anti-solvent precipitation methology[13]

The appropriate molar ratio of ethanol 50 ml in a 100 ml round bottle flask and incorporated embelin and soy-lecithin. After 30 minutes of ultrasonic treatment, the RBF mixture was completely homogenised. For the next three hours, the solution was maintained at a temperature of no more than 550 degrees Celsius while being stirred by a magnetic stirrer. This mixture was 10 ml in volume and 10% concentration. The n-hexane 30 ml was added to this solution, stirred slowly for the purpose of making a precipitate. The precipitate was added drop by drop to a chitosan (0.25% w/v) 2% aqueous acetic acid (v/v) mixture that was being continuously agitated at 550C using a magnetic stirrer. Precipitated phytosome complex containing Embelin was placed in a desiccator overnight. The powdered phytosome compound containing the embelin was stored in a container of amber tint.

Rotary vaporizationmethodoloy[14]

Employing the rotary evaporation method, we were able to create three distinct phytosome formulations (EMBP4, EMBP5, and EMBP6).

The correct molar ratios of embelin as well as soy lecithin were introduced to a Rotavapour RBF. 50 ml of ethanol were poured into the flask. For around 3 hours at a maximum temperature of 400 degrees Celsius, the flask was connected to a rotavapour as well as allowed to reflux.

In ethanol, the complex has been able to form a thin layer. This film was addedacetic acid (2% v/v) aqueous solutions of 0.25% w/v chitosan drop by drop, while the solution was being heated and stirred with a magnetic stirrer.

Precipitated phytosome complex containing Embelin was stored in a desiccator overnight. The powdered phytosome compound containing the embelin was stored in a container of amber tint.

Table 1: Composition of EMBP (Embelin loaded phytosome complex).

Phytosomes		EMBP1	EMBP2	EMBP3	EMBP4	EMBP5	EMBP6
Drug: Phospholipid (Molar ratio)	Drug (Embelin)	1	1	1	1	1	1
	Phospholipid (Soya lecithin)	1	1.5	2	1	1.5	2
Polymer (Chitosan) (%w/v)		0.25	0.25	0.25	0.5	0.5	0.5
Solvent (Ethanol) ml		50	50	50	50	50	50
Solvent (n-Hexane) ml		30	30	30	30	30	30

In order to prepare the standard calibration graph of pure Embelin, 10 mg of Embelin had been mixed in a volumetric flask and volume were correctedwith methanol to achieve a drug content of 100 g/ml of solution.

The calibration graph for embelin purity: Embelin standard stock solutions were diluted to 10, 20, 40, 60, 80, as well as 100 g/ml. By using a UV spectrophotometerfor absorbance at a wavelength of 289 nm. Every measurement was repeated three times to ensure precision in the final findings. Thespectra were recorded while a blank spectrum of methanol was also recorded at a 200-800 nm. The absorption of all solutions was measured, as well as a calibration curve of volume vs absorbance were constructed.

Assessment of Embelin loaded phytosome complex[15,]

Proportion yield of Embelin loaded phytosome complex[16]

Dry weights as well as measures were taken for every phytosome complex formulation containing Embelin. The percent yield of each free-floating microspheres was calculated by usingthe preceding equation:

$$\text{Percentage yield} = \frac{\text{Practical yield}}{\text{Theoretical yield}}$$

Where;

Practical yield:Prepared phytosome weight

Theoretical yield: Initial weight of Embelin, phospholipid and polymer

Determination of particle size of EMBP (Embelin loaded phytosome complex) [17]

Preparations of phytosome compounds embelin were analysed for particle size using a particle size analyser as well as the dynamic light scattering (DLS) technique (UK Malvern, Zetasizer-2021). Dispersing the synthesized Embelin-loaded phytosome compound in deionized water allowed us all to measure its size of the particles. The process was repeated three times and then each time temperature was increased to 250 degrees Celsius.

Assessment of morphology of surface

The surface morphology wasobserved by using scanning electron spectroscopy (Model JSM-5660LV) and used to look at the Embelin-loaded phytosome complex with the optimized formula (i.e., EMBP5). Scanning electron microscopy microphotographs were used to examine the EMBP outer surface.

***In-vitro*Immobilizationof EMBP (Embelin loaded phytosome complex)[18]**

By using UV-Visible spectrophotometerto identify the phytosome complex formulations containing Embelin. 1g EMBP(containing 10 mg of embelin) was dissolved in 50 ml of methanol in a beaker. After the ingredients of the beaker had been stirred for four hours, they were permitted to sit at room temperature for another hour. After 15 minutes of centrifugation at 2000 rpm, the clear supernatant liquid was recovered from the beaker. As the liquid was being centrifuged, it was filtered through 0.45 kPa of Whatman filter paper. Utilizing a UV-Visible double beam spectrophotometer (Shimadzu-1800, Japan) for the absorbance of this solution was measured at 288.7 nm, after it had been properly diluted. There were three repetitions of each measurement. To get a rough estimate of drug entrapment efficiency, the preceding formula was used.

$$\text{Drug entrapment efficiency (\%)} = \frac{\text{Total amount of drug} - \text{Amount of free drug}}{\text{Total amount of drug}} \text{ x } 100$$

EMBP *in-vitro* release patterns

Every phytosome combination containing Embelin underwent in-vitro drug release (dissolution) investigation using a USP type I, six station disintegration test device. The dissolving test apparatus's basket was makeupup to 900 cc and phosphate buffer pH 6.8. The experimental conditions were 37 2°C as well as 100 rpm. A 10 mg phytosome complex containing embelin was dispersed throughout the solvent. At certain intervals, a 5.0-ml sample was obtained (0, 30, 60, 120, 180, 240, 300, 360, 420, 480, 600, 720 m). After collecting the sample, it was filtered with Whatman filter paper. Each time, an identical amount of new phosphate buffer was injected to keep the sink at its original concentration. Researchers used a UV-VIS spectrophotometer set to 288.7 nm and a blank of phosphate solution to assess the quantity of Embelin throughout the dissolving agent by diluting the specimens with phosphorus solution.

Embelin-loaded phytosome complex: research on drug release kinetics

To investigate how drugs are released from the microspheres, in vitro dissolution data was fit using Higuchi's framework, first order rate kinetics, and Zero order model kinetics.

FINDINGSAS WELL ASANALYSIS[19]

Analysis of drug-excipient interaction

In this research, differential scanning calorimetry and fourier transform infrared (FTIR) spectroscopy were both used (DSC).

Table 2 and Fig. (1, 2) shown, IR spectrum of Embelin standard as well as inactive ingredients (soy lecithin + chitosan) were compared. Standard Embelin as well as the inert ingredients employed to create phytosomes exhibited no interaction with one another.

Table 2: Analysis of FTIR standard Embelin and with excipients.

Characteristic stretching and bending		C-O Stretching	C=O Stretching	C-H Stretching (methyl)	C-H Stretching (aromatic)	O-H (Stretching OH group)
Standard Embelin	Wave numbers (cm^{-1})	1125.56	1615.01	2845.02	2918.72	3311.52
Embelin+Soya lecithin+Chitosan		1120.23	1621.21	2852.32	2922.23	3314.56



Fig 1: Embelin FT-IR spectra.



Fig 2: Embelin FT-IR spectra and excipients (Embelin plus soy lecithin plus chitosan).

DSC had also been utilised to investigate the traditional Embelin's acceptability with the formulation excipients (DSC-60, Japan). The DSC of standard Embelin shows three thermally activated maxima at temperatures of 88.50, 144.50, and 231.50 degrees Celsius, which coincide to the melting temperature, breakdown, as well as water loss correspondingly (Fig. 3). For the physical mixing of these three substances, three endothermic measurements were made at 102.1°C for chitosan, 143.21°C for embelin, and 158.7°C for soya lecithin (Fig; 4).



Fig.3: EmbelinDSC thermogram.



Fig. 4:Embelin DSC thermogram of a natural mixture that includes soy lecithin and chitosan.

Standard Embelin's maximum concentration was calculated, as well as a calibration curve was made.

Using a UV-VIS double beam spectrophotometer for determination of Standard Embelin concentrations. Optimum value for typical Embelin was calculated at a 288.7 nm (Fig;5)



Fig 5: Embelin UV spectra.

The absorption of standard Embelin against methanol concentrations was plotted to create a standardized calibration graph (Fig;6).



Fig 6: Embelin Calibration curve.

Embelinloaded in phytosome complexes were tested for their In-vitro entrapment effectiveness, particle size, and percentage yield.

The percentage yields were determined of each formulation of the Embelin-loaded phytosome complex that was sufficiently dried. Yield percentages ranged from 86.20±0.53 for the EMBP4 formulation to 60.00±0.33 for the EMBP6 formulation. (Table;3). The average diameter of dried Embelin-loaded phytosome complex varies from 345.451±1.231 nm to 485.32±1.213 nm, as shown in Table 6,7, with the diameter being 345.45±1.231 nm for Formulation EMBP5 (Table 3).

According to the data in Table 6.7, the entrapment effectiveness of the phytosome complex that has been loaded with embelin is between 64.99±1.546 and 81.78±1.151%. A total of 81.78±1.151% of the embelin was captured by the phytosome complex formulation (EMBP5). (Table 3).

Table 3: Percentage yield, Particle size determination and *In-vitro*immobilization of Embelin loaded phytosome complex.

S. No.	1	2	3	4	5	6
Formulations	EMBP1	EMBP2	EMBP3	EMBP4	EMBP5	EMBP6
Percentage yield	65.80 ± 0.21	74.60 ± 0.37	70.53 ± 0.33	76.32 ± 0.53	86.20 ± 0.67	60.00 ± 0.33
Mean diameter of Embelin loaded phytosome complex (nm)	485.32 ± 1.213	387.47 ± 1.373	436.37 ± 2.361	456.26 ± 1.761	345.45 ±1.231	451.39 ±7.316
Entrapment efficiency (%)	73.31 ± 1.323	77.62 ± 1.034	64.99 ± 1.546	74.23 ±1.832	81.78 ± 1.151	66.69 ± 1.321

SEM assessment

SEM micrographs provide a quick visual summary of the phytosome complicated with Embelin loaded, including its surface morphology as well as solid-state features. Photos taken using a scanning electron microscope reveal that the phytosomes in the best formulation (EMBP-5) of the Embelin-loaded phytosome compound are much less round, have a smooth and rough surface, as well as being somewhat aggregated. Phytosomes often manifested as single bodies or clusters of unfused phytosomes (Fig; 7, 8).



Fig 7: Embelin-loaded phytosome complex in improved fabrication (EMBP5) by SEM photomicrography.

***In-vitro* issue patterns of embelin from EMBP**

The release of embelin from embelin loaded phytosome complex by employing a USP type I, six station dissolution apparatus for in-vitro drug release pattern. The sample was taken in aliquots at regular times. and analysed using spectrophotometry at 288.7 nm. Predictability and control may be shown in Table 4 of the results from in-vitro dissolution investigations, as well as (Fig. 9 and 10).

Table 4: *In vitro* release profiles of Embelin from Embelin loaded phytosome complexes.

Time (h)		0	0.5	1	2	3	4	5	6	7	8	10	12
Cumulative percentage (%) of drug release	EMBP1	0	3.63	10.25	21.43	33.71	44.43	52.24	61.27	66.74	72.72	77.56	78.23
	EMBP2	0	5.33	13.26	24.31	35.48	46.71	54.21	62.74	66.56	71.64	78.44	79.32
	EMBP3	0	7.21	15.13	27.58	38.36	49.71	57.72	63.43	67.67	71.31	80.06	81.74
	EMBP4	0	3.21	14.12	23.54	33.24	44.21	55.35	62.35	66.45	72.22	77.45	79.92
	EMBP5	0	4.32	14.32	24.43	35.54	46.35	58.21	66.55	69.4	74.58	80.45	86.52
	EMBP6	0	2.78	12.54	22.24	32.12	42.12	57.22	63.41	65.35	71.77	76.42	78.21



Fig 8:*Embelin loaded phytosome complexes have distinct in vitro embelin release patterns.*(EMBP1, EMBP2 and EMBP3).



Fig 9:*Embelin loaded phytosome complexes have distinct in vitro embelin release patterns.*(EMBP4, EMBP5 and EMBP6).

Drug release kinetic researches of Embelin loaded phytosome complex[20]

We used Higuchi's model, first order model kinetics, as well as zero order model kinetics to model the in vitro data. The best fit between the release data and Higuchi's model, first order, and zero order was used to calculate the formulation release kinetics. Due to the drug's disintegration into the surface, it was attached to, initial drug releases were noticeably elevated in all formulations. The rate of release gradually decreased due to dispersion.

Table 5 shows that fickian diffusion as well as first kinetics were employed for the discharge of embelin from the compound of phytosomes containing embelin (concentration dependant).

Table 5: Values of various kinetic models' regression co-efficient (R2).

Mechanism of drug release			Release of drugs on zero orders kinetics	Release of drugs on zero orders kinetics	Diffusion release kinetics using Higuchi's model	Best fit model
EMBP1	Regression co-efficient values	(R^2)	0.916	0.9819	0.9616	First order & Higuchi's Model
EMBP2			0.9137	0.9887	0.9712	First order & Higuchi's Model
EMBP3			0.9091	0.975	0.9784	First order & Higuchi's Model
EMBP4			0.9169	0.9838	0.9578	First order & Higuchi's Model
EMBP5			0.9248	0.9956	0.9707	First order & Higuchi's Model
EMBP6			0.9065	0.9708	0.9578	First order & Higuchi's Model

Experimental protocol for animal study

Chemicalsandinstrumentation

Paracetamol (Horizon bioceutical, India), Silymarin (Amgis life science, India), Test kits for ALT and AST, LDH, Albumin, ALP and bilirubin from Span Diagnostics Ltd, (PharmaSpec UV-1700, Shimadzu).

Animals used in experiments

In the Axis Colleges animal facility in Kanpur, we keep male Wistar rats that weigh between (150 and 190g) that procured from Animal house of Central Drug Research Institute (CDRI)Lucknow. All animals were kept for acclimatization in individual cages for oneweek before commencement of the experiment, with the relative humidity set between 50 and 60%, the temperature set between (23±2) degrees Celsius, as well as a 12-hour on/12-hour off light/dark schedule.

Rats were maintained on special a diet and water ad libitum throughout their housing period. Institutional Animal Ethics Committee (IAEC) clearance was acquired from the Axis Institute of Pharmacy, Axis Colleges, Kanpur (approved number: AC/AIP/IAEC/01/23), and every experiment adhered to the recommendations provided forth by the Committee for the Purpose of Control and Supervision of Experimental animals (CPCSEA).

Procedures for Conducting Experiments

There was a total of 25 rats, which were evenly distributed throughout 5 groups of 5. Group I was the control group; the animals there were given a vehicle (1% CMC) for the whole 8 days.

For the first seven days, animals in Group II received a vehicle treatment, and then, on Day 8, a single dosage of PCM 5 g/kg orally was given to cause hepatotoxicity.

Group III, IV, and V animals were given EMBP2 (50mg/kg body weight), EMBP5 (100mg/kg body weight), and silymarin (100mg/kg/day) for seven days, and on the eight-day, hepatotoxicity was induced by givinga single dosage of PCM (5.0 g/kg body weight) orally. After 24 hours, rats were euthanized through retro-orbital plexus puncture under mild anaesthesia (ethyl ether). This was done so that blood could be drawn for analysis. Centrifugation was used to isolate the serum for 20 minutes at 3000 rpm and 4°C and prior to the assessment of several biochemical parameters[20]. After a double rinsing in ice-cold saline, we separated the liver tissues from each sample, dried them out, and weighed them. To determine the relationship between liver weight and overall body weight, liver weight was stated as a percentage of total body weight. Only a little piece of tissue was put into formalin for the purpose of histological examination.

Analyzing Liver Function Test

Standard kits such as those for albumin (ALB), alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST), bilirubin (BIL), cholesterol (CHOL) and total protein were used to determine the liver's activity (TP). Serum lactate dehydrogenase was measured using Accurex Biochemistry Pvt Ltd standard reagents from Mumbai, India (LDH). A UV spectrophotometer was used to quantify all enzymatic estimates, following protocols derived in full from the packaging inserts of commercially available kits.

Histopathological analysis[21]

Slices of liver were preserved in a 10% neutral formalin solution. Liver tissues were embedded in paraffin wax in the lab, and then slices were cut at 6 mm in thickness to study. The tissue sections were stained using dye solutions containing eosin and haemotoxylin. Photomicrographs were taken while examining the slides with a light microscope. Fibrosis, adipose infiltration, centrilobular necrosis, and lymphocyte infiltration were all seen.[22]

Result

A mean and standard error of the mean were used to show the data. In order to determine statistical significance, we first used the Student's t-test and then, with the support of the graph pad prism software, the Newman-Keuls test for individual comparisons. Statistical significance was assigned to a finding if the probability value was less than 5% ($p<0.05$).

The liver weight rose with PCM therapy from the normal control group I (3.05 ±0.07/100g) to (5.52 ±0.51/100g). This rise was statistically significant ($p <0.01$), (b. wt.).

Treated with (EMBP 50 mg/kg, ($p <0.05$) and EMBP 100 mg/kg, ($p< 0.01$) decline liver weight comparatively to PCM treatment (3.25± 0.17/100g body. wt.).

The EMBP-treated rats in Group IV were more similar to the control rats in Group V than to the EMBP-treated rats in Group III at the dose used in this study. In comparison to the rats in group II that received 100 mg/kg of EMBP, there was a statistically significant ($p<0.01$) difference in body weight and relative liver weight. Blood levels of AST (295.71 ±0.11 u/l), ALT (169.14 ±0.8 u/l), ALP (185.31 ±1.20 u/l), and LDH (682.32± 1.72 u/l) were all higher in the PCM-treated group II rats when compared to the normal control group I male wistar rats. Groups III and IV, who were given EMBP, had significantly reduced AST levels (199.86 ±1.28 u/l, ($p< 0.05$), and 129.75 ±1.98 u/l, ($p<0.01$), respectively). ALT (87.64± 2.072 u/l, ($p <0.05$), and 42.52± 2.312 u/l, ($p<0.01$), ALP (99.03± 1.43 u/l, ($p< 0.05$), and 85.72± 1.81 u/l, ($p< 0.01$), and LDH (523.14± 14.12 u/l, ($p< 0.05$) were all declined in group I than in group II.

As shown in Table 1, silymarin at 100 mg per kg significantly ($p<0.01$) declined the elevated levelsof AST, ALT, ALP, and LDH compared to PCM-treated group II, bringing them down to 92.02 ±2.57 u/l, 42.701.89 u/l, 72.24 ±3.04 u/l, and 367.13±5.33 u/l. The PCM-treated group II showed substantially ($p<0.01$) diminished serum ALB (2.10± 0.03 g/dl) and TP (3.47± 0.23 g/dl) while increasing bilirubin, in comparison to the control group I (4.01 ±0.01 g/dl, 6.12± 0.132 g/dl, 0.13±0.005 mg/dl, and 39.03±2.34 mg/dlrespectively). Silymarin at 100 mg per kg significantly ($p<0.01$) increased ALB (4.03 ±0.02 g/dl) and TP (5.57± 0.11 g/dl) compared to the PCM-treated group II, and also decreased bilirubin (1.00 ±2.040), ($p <0.01$).

Table 6 shown, the effect of EMBP on numerous liver-biomarkers in normative and treatment-nonstandard animal populations.

Treated group & liver biomarkers	Initial b. wt. (g)	Final b. wt. (g)	Liver wt. (g)	Relative liver wt.	AST (U/L)	ALT (U/L)	ALP (U/L)	LDH (U/L)	Bilirubin (mg/dl)	Cholesterol (mg/dl)	ALB (g/dl)	TP (g/dl)
Group I (Sham control) 1% CMC 1ml/kg body wt.	160 ± 3.99	185 ± 10.31	5.08 ± 0.42	3.05 ± 0.07	79.62 ± 0.85	38.03 ± 1.55	60.38 ± 1.62	334.30 ± 0.36	0.13 ± 0.005	39.03 ± 2.34	4.01 ± 0.01	6.12 ± 0.132
Group II (Toxic control) PCM 5mg/kg body wt.	142.2 ± 3.13	150 ± 3.91$^{\#}$	8.54 ± 0.26$^{\#}$	5.25 ± 0.51$^{\#}$	295.71 ± 0.11$^{\#}$	169.14 ± 0.8$^{\#}$	185.31 ± 1.20$^{\#}$	682.32 ± 1.72$^{\#}$	1.11 ± 0.096$^{\#}$	72.1 ± 2.03$^{\#}$	2.10 ± 0.03$^{\#}$	3.47 ± 0.23$^{\#}$
Group III EMBP2 (50mg/kg body wt). PCM5mg/kg body wt.	170 ± 2.02	180.3 ± 2.07*	6.90 ± 0.95^{ns}	3.25 ± 0.17*	199.86 ± 1.28*	87.64 ± 2.072*	99.03 ± 1.43*	523.14 ± 14.12*	1.002 ± .040*	59.2 ± 1.43*	3.25 ± 0.12*	4.52 ± .061*
Group IV EMBP 5 (100mg/kg body wt). PCM5mg/kg body wt.	180 ± 3.12	200 ± 3.42**	6.12 ± 0.32**	2.75 ± 0.35**	129.57 ± 1.98**	42.52 ± 2.312**	85.72 ± 1.81**	399.15 ± 29.87**	0.40 ± .001**	50.2 ± 1.81**	4.02 ± 0.02**	5.02 ± 0.20**
Group V Silymarin (100mg/kg body wt). PCM5mg/kg body wt.	178.1 ± 1.32	210.1 ± 3.34**	6.04 ± 0.20**	2.34 ± 0.092**	92.02 ± 2.15**	42.70 ± 1.89**	72.24 ± 3.04**	367.13 ± 5.33**	0.22 ± 0.103**	35.2 ± 1.10**	4.03 ± 0.02**	5.57 ± 0.11**

Results were shown as means SEM (n= 5), with a significance level of ($p <0.01$) when compared to group I (control), NS ($p > 0.05$), * ($p <0.05$), as well as ** (p 0.01) versus group II (control).



Images: The gross morphological and histological impacts of EMBP upon that liver are shown in image 1 as well as 2, correspondingly.

DISCUSSION

The purpose of this research was firstly preparedphytosomes from embeline (herbal drus). The embelin was loaded in phytosomes for specific site drug delivery other than convention dosage forms, so this current study is unique and increase the bioavailabity of embelin. After the fabrication of various doses of Embelin loaded phytosomes(EMBP) were studied on the male wistar rats for hepatoprotective potential. The hepatotoxicity was induced in rats by extremely high dosages of the pain reliever and fever reducer Paracetamol (PCM) cause potent hepatotoxic chemical that may cause rapid renal tubular as well as hepatic necrosis[23,24], which can be fatal for both animals and humans. In both experimental animals and people, an overdose may trigger liver dysfunction failures, centrilobular hepatic necrosis, and possibly even death[25]. PCM-induced hepatotoxicity is characterised in the laboratory by a decline in ALB and TP[26] and surges in ALP, ALT, AST, LDH, bilirubin and cholesterol similar to other types of acute inflammation and liver disease.According to experimental models of PCM-induced hepatotoxicity, hepatocellular damage occurs,according to the study, ALP, ALT, AST, bilirubin, cholesterol, and LDH levels in the blood elevated even as ALB and TP levels have dropped. In these PCM-impaired rats, the levels of AST, ALP, ALT, bilirubin, cholesterol and LDH were markedly ($p<0.05$ to $p<0.01$) declined by EMBP at 50 and 100 mg/kg. Photomicrographs of the liver's histology and test findings for liver function were related to one another. In group II, PCM deficiency was clearly visible in liver apoptosis, cell death, and leukocyte infiltration. The PCM-induced histological alterations were stopped by EMBP therapy. These studies demonstrated that the EMBP may protect against PCM-induced hepatotoxicity by reducing elevated markers of liver damage and function. Hepatoprotection may be given by EMBP[27,28] because to the antioxidant capabilities of the Embelin loaded phytosomes complex, which diminish the oxidative stress brought on by PCM, as well as other characteristics, like analgesic and anti-inflammatory effects, which minimize the inflammatory liver damage.

Protecting Wistar male rats from paracetamol-induced hepatotoxicity, as evaluated by considerable reduction in ALP, AST, ALT, bilirubin, cholesterol, as well as LDH as well as increased the level of ALB and TP concentrations, as well as preventing PCM-induced changes in the liver's histopathology, demonstrates the hepatoprotective properties of embelin-loaded phytosomes complex (EMBP).

Active constituents of Embelia ribes Burm. f. was a compound called embelin. According to the literature, embelin has a wide variety of pharmacological applications. Research into phytosomes has the potential to boost medicinal effectiveness while reducing dosing frequency. To create phytosome complexes loaded with embelin, Both the Rotary evaporation methodology and the anti-solvent precipitation approach were employed. Embelin-loaded phytosome formulations in six distinct forms (EMBP1, EMBP2, EMBP3, EMBP4, EMBP5, and EMBP6) were developed. It was found that Formulation EMBP5 was the most optimal of the six formulations tested. The diameter of EMBP5 is the smallest, measuring in at 345.45 ±1.231. From 64.99 1.546 to 81.78 ±1.151%, the entrapment effectiveness of the Embelin-loaded phytosome complex varies. The immobilization of the embelin-loaded phytosome complex formulation (EMBP5) is greatest at 81.78 1.151%. Micrographs taken using a scanning electron microscope (SEM) of an improved formulation (EMBP5) of an Embelin-loaded phytosome complex revealed that the phytosomes are much less spherical, with smooth and rough surfaces, and are somewhat aggregated. Researchers have shown that the phytosome extended-release pattern has a 12 hour half-life and an 86.52% release rate in vitro.

CONCLUSIONS

EMBP has hepatoprotective properties as shown by its ability to protect male wistar rats from acetaminophen-induced hepatotoxicity as measured by significant reductions in AST, ALT, ALP, LDH, cholesterol, and bilirubin and increases in ALB and TP concentrations, as well as the prevention of PCM-induced changes to the liver's histopathology.

Conflicts of interest

None

ACKNOWLEDGEMENTS

Authors are thankful to the Axis Institute of Pharmacy, Axis Colleges, Kanpur for providing all necessary facilities related to current research work.

ABBREVIATION

(FTIR) : (Fourier transform Infrared Spectroscopy
(DSC) : (Differential Scanning Calorimetry))
(IAEC) : Institutional Animal Ethics Committee
(CPCSEA) : Committee for the Purpose of Control and Supervision of Experimental Animals
(ALB) : Albumin
(ALP) : Alkaline phosphatase
(ALT) : Alanine transaminase
(AST) : Aspartate aminotransferase
(BIL) : bilirubin
(CHOL) : cholesterol
(TP) : total protein
(LDH) : lactate dehydrogenase
UV : Ultra-violet spectrophotometer
(EMBP) : Embelin loaded Phytosomes
(PCM) : Paracetamol
(CMC) : carboxy-methyl cellulose
(DLC) : Dynamic light Scattering
(kPa) : Pressure drop
(RPM) : Round per minutes
(v/v) : Volume by Volume
(u/l) : Micro liter
(g/dl) : Gram per deciliter
(Wt) : weight
(g) : gram
(R^2) : Regression Co-efficient
(%) : Percentage

REFERENCES

1. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev 2009;14(3):226–46.
2. Manach C,Scalbert A,Morand C,Rémésy C,Jiménez L. Polyphenols: food source and bioavailability. Am J Clin Nutr 2004;79(5):727–47.
3. Teng Z,Yuan C ,Zhang F,et al.Intestinal absorption and first-pass metabolism of polyphenol compounds in rat and their transport dynamics in caco-2 cells. PLoS One 2012;7(1):29647.
4. Manach C,Scalbert A,Morand C,Rémésy C,Jiménez L. Polyphenols: food source and bioavailability. Am J Clin Nutr 2004;79(5):727–47.

5. Ting Y,Jiang Y,Ho CT,Huang Q. Common delivery systems for enhancing *in vivo* bioavailability and biological efficacy of nutraceuticals. J Funct Foods 2014; 7:112–28
6. Saraf S., Khan, J., Alexander A., Ajazuddin & Saraf S., Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives, J. Control. Release, 2013,168(1), 50–60.
7. More MS, Shende MA, Kolhe DB, Jaiswal NM. Herbosomes: herbo-phospholipid complex an approach for absorption enhancement. International journal of biological & pharmaceutical research 2012; 3(8):946-955.
8. Podolak, I., Galanty, A., Janeczko, Z., Cytotoxic activity of embelin from *Lysimachia punctata*, Fitoterapia 76 (2005) 333- 335.
9. Kumar S, Deshmukh R (2017) Embelin as a Potential Drug Molecule: A Review. J Pharmacogn Nat Prod 3(3): 2017 144.
10. Rajendra Awasthi, Giriraj T Kulkarni, Vivek K Pawar, Phytosomes: an approach to increase the bioavailability of plant extracts, International Journal of Pharmacy and Pharmaceutical Sciences, 2011; 3(2): 1-3.
11. Nilesh Jain Brahma P Gupta, Navneet Thakur, Ruchi Jain, Jitendra Banweer, Deepak Kumar Jain, Surendra Jain, Phytosome: A Novel Drug Delivery System for Herbal Medicine, International Journal of Pharmaceutical Sciences and Drug Research, 2010; 2(4): 224-228.
12. Patel J,Patel R,Khambholja K,Patel N. An overview of phytosomes as an advanced herbal drug delivery system. Asian J Pharma Sci 2008;4(6):363–71.
13. Gupta N K, Dixit VK, Development and evaluation of vesicular system for curcumin delivery, Archieves of Dermatological Research, 2011, 303, 89-101.
14. Sikarwar MS, Sharma S, Jain AK, Parial SD. Preparation, characterization and evaluation of marsupsin-phospholipid complex. *AAPS PharmSciTech* 2008;9(1):129-37.
15. Maiti K. Mukherjee, K. Gantait, A, Saha, BP. Mukherjee, PK Curcumin-phospholipid complex: Preparation therapeutic evaluation and pharmacokinetic study in rats. Current Drug Delivery, 2006: 31-38.
16. Semalty A, Semalty M, Singh DM, Rawat SM. Preparation and characterization of phospholipid complexes of naringenin for effective drug delivery, Fitoterapia, 2009;(8):59-62.
17. Vishwakarma DK, Gehlaut P, Mishra JN, Phytosomes- As a Novel Approach of Herbal Drug Delivery System,2022;31-37.
18. Priti KM, Vishwakarma DK, Mishra JN, Development and in-vitro evaluation of embelin (a phytoconstituent) loaded phytosome complex, IJPSR2022;2154-2162.
19. Jafri MA, Subhani MJalis, JavedKalim, SinghSurender. Hepatoprotective activity of leaves of *Cassia occidentalis* against paracetamol and ethyl alcohol intoxication in rats, 1999; vol 66 (3):355-361.
20. Alam J, Mujahid Md, Badruddeen, Jahan Y, Bagga P, Rahman A. Hepatoprotective potential of ethanolic extract of Aquilaria agallocha leaves against paracetamol induced hepatotoxicity in SD rats,JTCM 2017;(7): 9-13.
21. Goldin RD, Ratnayaka ID, Breach CS, Brown IN, Wickramasinghe SN. Role of macrophages in acetaminophen (paracetamol)-induced hepatotoxicity. J Pathol. 1996; 179:432-435.
22. Hinson JA, Bucci TJ, Irwin LK, Michael SL, Mayeux PR. Effect of inhibitors of nitric oxide synthase on acetaminophen-induced hepatotoxicity in mice. Nitric Oxide. 2002; 6:160-167. 23.
23. Savides MC, Oehme FW. Acetaminophen and its toxicity. J Appl Toxicol. 1983;3: 96-111.
24. Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J. 1966; 2:497-499.
25. Chaturvedi P, George S, Machacha CN. Protective role of Raphanus sativus root extract on paracetamol-induced hepatotoxicity in albino rats. Int J Vitam Nutr Res. 2007; 77:41-45.
26. Chaturvedi S, Drabu S, Sharma M. Anti-inflammatory and analgesic activity of Tamarix gallica. Int J Pharm Pharm Sci. 2012; 4:653-658